학술논문
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up
Document Type
Article
Author
Source
In Journal of Thoracic Oncology April 2024
Subject
Language
ISSN
1556-0864